论文部分内容阅读
Crizotinib是由辉瑞公司开发的,主要用于治疗通过FDA批准的检测方法诊断为间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移的非小细胞肺癌(NSCLC),它是目前惟一个治疗该类疾病的药物。Crizotinib于2011年8月
Crizotinib was developed by Pfizer and is used primarily to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) diagnosed as anaplastic lymphoma kinase (ALK) by an FDA-approved assay that is currently the only treatment for this Diseases of the drug. Crizotinib in August 2011